Serum levels of ceruloplasmin, properdin factor B and copper in lymphoma patients

Area of Science:

• Clinical Chemistry and Hematology
• Oncology and Cancer Research

Background:

• Hodgkin's Disease and non-Hodgkin's lymphoma are significant hematologic malignancies.
• Biomarkers for monitoring disease progression and treatment response are crucial in oncology.

Purpose of the Study:

• To evaluate serum levels of Ceruloplasmin (CER), Properdin Factor B (PFB), and Copper (CU) in patients with Hodgkin's Disease (HD) and non-Hodgkin's lymphoma (NHL).
• To determine the potential utility of these markers, particularly CER and CU, in monitoring HD.

Main Methods:

• Serum samples from 40 HD patients and 46 NHL patients were analyzed.
• Ceruloplasmin (CER) and Properdin Factor B (PFB) concentrations were measured using rate nephelometry.
• Copper (CU) concentrations were determined via the bathocuproine colorimetric method.

Main Results:

• Elevated serum levels of CER and CU were observed in patients with HD and NHL.
• The study demonstrated that CER, alongside the established marker CU, shows promise for monitoring Hodgkin's Disease.
• PFB levels were also evaluated but CER and CU showed greater relevance for HD monitoring.

Conclusions:

• Serum Ceruloplasmin (CER) and Copper (CU) levels can serve as valuable indicators for monitoring Hodgkin's Disease.
• These biochemical markers may aid clinicians in assessing disease status and treatment efficacy in HD patients.